Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Keratosis, Actinic 3Carcinoma, Basal Cell 3Skin Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Depression 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Therapeutics 28Psychiatric Rehabilitation 21Surveys and Questionnaires 14Cognitive Behavioral Therapy 12Psilocybin 8Methods 8Ketamine 8Early Intervention, Educational 8Saline Solution 7Yoga 6Mindfulness-Based Cognitive Therapy 6Interviews as Topic 6Esketamine 6Psychosocial Intervention 5Mindfulness 5Escitalopram 5Behavior Therapy 5Methylphenidate 4Exercise Therapy 4Exercise 4Educational Status 4Counseling 4Control Groups 4Acupuncture Therapy 4Standard of Care 3Psychotherapy 3Palliative Care 3Niacin 3Mindfulness-Based Stress Reduction 3Melatonin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Depression × Niacinamide × Clear all
NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡